⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
Cell Therapy Market Size Set to More Than Double by 2030 -- North America Leads, While Asia-Pacific Emerges as the Fastest-Growing Region, Says Mordor Intelligence
prnewswire.com
NVS
BMY
JNJ
SRPT
GILD
TMO
DHR
SART
MRK
BDX
Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer
businesswire.com
MRK
FDA Approves KEYTRUDA ® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev ® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
businesswire.com
MRK
Levi & Korsinsky, LLP Investigates Merck Sharp & Dohme LLC Data Breach
accessnewswire.com
MRK
Prostate Cancer Drugs Market to Reach USD 28.10 Billion by 2033 | According to DataM Intelligence
prnewswire.com
BIIB
MRK
JNJ
PFE
AZN
BMY
GILD
EXEL
RDVY
CRIS
VRTX
INCY
ABBV
LULU
VIR
FGEN
HALD
VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future
prnewswire.com
AZN
LLY
MRK
Zapata Quantum Adds Financial Veteran William Klitgaard to Board as Company Aims to Relist on National Exchange
globenewswire.com
ZPTA
XLNX
SYNH
AVST
CERT
BCRA
LHCG
AMZN
GOOG
MSFT
IBM
ORCL
MRK
DGX
ANTM
UNH
AMGN
GILD
BMY
PFE
ABBV
LRCX
KLAC
ADI
NXPI
QCOM
INTC
AMD
NVDA
MU
SMCI
CRWD
PANW
ZS
SNOW
DDOG
FTNT
TEAM
CRM
NOW
ADBE
INTU
PAYX
ADP
CTAS
WBA
CVS
CI
CNC
ELV
REGN
VRTX
BIIB
ALXN
AZN
NVS
ROG
SNY
XRAY
SYK
BSX
TMO
ILMN
EXAS
MDLZ
KHC
PEP
KO
MCD
SBUX
YUM
CMG
QSR
DNKN
LVS
WYNN
MGM
LULU
NKE
UA
ADDYY
PVH
RL
GPS
TJX
ROST
BBY
HD
LOW
SPG
PLD
AMT
EQIX
CCI
SBAC
PLTR
AI
UPST
SOFI
COIN
PYPL
SQ
AXP
V
MA
JPM
BAC
WFC
GS
MS
SCHW
ETFC
RJF
LPLA
BEN
IVZ
ABR
O
PSA
GOOGL
Hepatitis B and C Therapeutics Market Surges to US$17.02 Billion in 2024 as Innovation, National Screening Policies, and Next-Gen Antivirals Transform Global Care | According to DataM Intelligence
prnewswire.com
GILD
ABBV
MRK
BMY
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
businesswire.com
MRK
European Commission Approves Subcutaneous Administration of KEYTRUDA ® (pembrolizumab) for All Adult Indications Approved in the European Union
businesswire.com
MRK